{
    "root": "49c998c7-d0b4-4527-8e34-dc5edc59a40f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "iwilfin",
    "value": "20241213",
    "ingredients": [
        {
            "name": "EFLORNITHINE HYDROCHLORIDE",
            "code": "4NH22NDW9H"
        },
        {
            "name": "microcrystalline cellulose",
            "code": "OP1R32D61U"
        },
        {
            "name": "silicon dioxide",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "magnesium stearate",
            "code": "70097M6I30"
        }
    ],
    "indications": "IWILFIN (eflornithine) is indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy.",
    "contraindications": "Prior to initiation of IWILFIN, perform baseline audiogram, complete blood count, and liver function tests. ( 2.1 , 5.3 ) Recommended dosage of IWILFIN is based on body surface area (see Table 1 ). ( 2.2 ) IWILFIN is taken orally twice daily with or without food until disease progression, unacceptable toxicity, or for a maximum of two years. ( 2.2 ) IWILFIN tablets may be swallowed whole, chewed, or crushed and mixed with soft food or liquid. ( 2.5 )",
    "warningsAndPrecautions": "IWILFIN (eflornithine) is available as 192 mg round, white to off-white tablets imprinted with EFL on one side and 192 on the other side; approximately 11 mm in diameter and supplied as follows:\n                  \n                     Bottle of 100 tablets containing desiccant, NDC 78670-150-01",
    "adverseReactions": "None."
}